ACRS vs EMN · rev $3.6M vs P/E 21, rev $9.38B
Aclaris Therapeutics Inc (ACRS) versus Eastman Chemical Company (EMN) — a side-by-side from cached financials, not a winner call.
Aclaris Therapeutics Inc (ACRS) is a biotechnology company listed on NASDAQ.
Eastman Chemical Company (EMN) is a specialty chemicals company listed on US.
Latest reported ACRS revenue for 2026-06-30 was $3.6M. Net income was -$41.3M. Revenue was up 81.6% from 2026-03-31 to 2026-06-30. ACRS currently screens at market cap $615.9M.
Latest reported EMN revenue for 2024-12-31 was $9.38B. Net income was $908.0M. Revenue was up 1.9% from 2023-12-31 to 2024-12-31. EMN currently screens at market cap $8.21B and trailing P/E 20.8.
ACRS currently screens at market cap $615.9M. EMN currently screens at market cap $8.21B and trailing P/E 20.8.
Not investment advice. Open the ACRS and EMN stock pages for the full models.
Not investment advice.